Cargando…

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy

Detalles Bibliográficos
Autor principal:	Kang, Shin-Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372797/ https://www.ncbi.nlm.nih.gov/pubmed/22707885 http://dx.doi.org/10.3904/kjim.2012.27.2.151

Ejemplares similares

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?
por: Grandin, E. Wilson, et al.
Publicado: (2021)

A glimpse of diabetic nephropathy
por: Khoshjou, Farhad
Publicado: (2016)

Effect and Mechanism of Phosphodiesterase Inhibitors on Trabecular Outflow
por: Kim, Jae Woo, et al.
Publicado: (2019)

Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice
por: Seo, Da Hea, et al.
Publicado: (2022)

Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis
por: Zheng, Shirong, et al.
Publicado: (2016)

Diabetic Nephropathy: From Pathophysiology to Treatment
por: Shen, Ziyan, et al.
Publicado: (2017)

Phosphodiesterase Inhibitor Improves Renal Tubulointerstitial Hypoxia of the Diabetic Rat Kidney
por: Sun, Hui-Kyoung, et al.
Publicado: (2012)

Experimental Models of Type-2 Diabetic Nephropathy
por: Tomino, Yasuhiko, et al.
Publicado: (2012)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Combat Diabetic Nephropathy: From Pathogenesis to Treatment
por: Gohda, Tomohito, et al.
Publicado: (2014)

MicroRNAs for podocyte injury in diabetic nephropathy
por: Morishita, Yoshiyuki
Publicado: (2021)

Vitamin D in diabetic nephropathy
por: Prabhu, RA, et al.
Publicado: (2018)

Biomarkers of progression in diabetic nephropathy: The past, present and future
por: Lee, Chi-Ho, et al.
Publicado: (2015)

Where do we stand on human diabetic nephropathy?
por: Ryong Cha, Dae
Publicado: (2013)

Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Avenues
por: Oltean, Sebastian, et al.
Publicado: (2017)

Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”
por: Ruiz-Ortega, Marta, et al.
Publicado: (2020)

Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes
por: Hackett, Geoffrey, et al.
Publicado: (2017)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
por: Halverscheid, Leonie, et al.
Publicado: (2009)

Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer
por: Domvri, Kalliopi, et al.
Publicado: (2017)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy
por: Wen, Jian-jun, et al.
Publicado: (2016)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

Differential effects of two phosphodiesterase 4 inhibitors against lipopolysaccharide-induced neuroinflammation in mice
por: Kang, Dong Ho, et al.
Publicado: (2023)

The real culprit behind diabetic nephropathy: impaired renal autoregulation?
por: Liu, Ruisheng
Publicado: (2017)

Role of Phosphodiesterase in the Biology and Pathology of Diabetes
por: Kilanowska, Agnieszka, et al.
Publicado: (2020)

Does nondiabetic renal disease exacerbate diabetic nephropathy in patients with type 2 diabetes?
por: Park, Cheol Whee
Publicado: (2013)

Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study
por: Song, Seung-Hun, et al.
Publicado: (2021)

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
por: Simkova, Vladislava, et al.
Publicado: (2007)

How much glycemic control is needed to prevent progression of diabetic nephropathy?
por: Park, Tae Sun
Publicado: (2012)

Nonalbuminuric Renal Insufficiency: Can It Be a Novel Category of Diabetic Nephropathy?
por: Tanaka, Masami, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_frvem8jdj78lkbu1m0qlc0j835